Marker Therapeutics Inc (MRKR)

[Inoviorulez]

I think the advantage for Maker being that it is in multiple phase 1/2 studies which in essence means phase 2. That TAA-T appears to be only phase 1. Also Marker seems to be generating solid data alone as a monotherapy. maybe checkpoint inhibitors could be explored in the future to see if they mesh well. IMO it will come from a big pharma deal. Such companies like Marker would be a massive buy for a big pharma. Keytruda or Opdivo would work as PD-1/PD-L1 inhibitors to open up the tumor to attack (because tumors have suppressive microenvironments), then Marker's drugs would incite T-cells and the entire arm of the immune system to attack all at once.